Anne Rogiers

7PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCentral nervous systemNgā taiohi me ngā whānau Māori (Māori youth and family)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 14, 2026
The Effectiveness of a Multidisciplinary Integrative Survivorship Program for Cancer-Related Cognitive Impairment: A Prospective Cohort Study.

Nathalie Vanlaer, Camille Testaferrata, Lynn Decabooter

|May 11, 2024
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study.

Nathalie Vanlaer, Iris Dirven, Bart Neyns

|Oct 14, 2023
Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.

Anne Rogiers, Laurence Willemot, Laura McDonald

|Jan 09, 2021
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.

Gil Awada, Yanina Jansen, Julia Katharina Schwarze

|Aug 11, 2020
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab.

Anne Rogiers, Christophe Leys, Justine Lauwyck

|Nov 21, 2019
Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.

A Rogiers, C Leys, J De Cremer

Pageof 2

Frequent Collaborators

6 joint publications

Bart Neyns

2 joint publications

Gil Awada

2 joint publications

Julia Katharina Schwarze

2 joint publications

Iris Dirven